Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 7% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded down 7% during trading on Monday . The company traded as low as $18.34 and last traded at $18.58. 72,167 shares traded hands during trading, a decline of 70% from the average session volume of 241,564 shares. The stock had previously closed at $19.99.

Wall Street Analysts Forecast Growth

DNTH has been the subject of several research reports. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. Guggenheim restated a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $54.33.

Dianthus Therapeutics Price Performance

The firm has a market cap of $559.62 million, a price-to-earnings ratio of -6.97 and a beta of 1.82. The firm has a fifty day simple moving average of $21.78 and a two-hundred day simple moving average of $24.09.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DNTH. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth $26,000. KLP Kapitalforvaltning AS acquired a new stake in Dianthus Therapeutics during the 4th quarter worth about $33,000. KBC Group NV acquired a new stake in Dianthus Therapeutics during the 4th quarter worth about $35,000. BNP Paribas Financial Markets acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at about $59,000. Finally, AlphaQuest LLC lifted its holdings in shares of Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after buying an additional 3,072 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.